Older adults experiencing irreversible blindness may now be able to see thanks to a system relying on a wireless retinal implant and high-tech glasses ...

Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.